Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human
immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double …

Despite the success of antiretroviral therapy (ART), there is currently no HIV cure and
treatment is life long. HIV persists during ART due to long-lived and proliferating latently …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

In people living with HIV (PLWH) who are failing or unable to access combination
antiretroviral therapy (cART), monocytes and macrophages are important drivers of …

Despite antiretroviral therapy, HIV-1 persists in memory CD4+ T cells, creating a barrier to
cure. The majority of HIV-1 proviruses are defective and considered clinically irrelevant …

Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …

One of the most explored therapeutic approaches aimed at eradicating HIV-1 reservoirs is
the “shock and kill” strategy which is based on HIV-1 reactivation in latently-infected cells …